目的:探讨低剂量米非司酮治疗围绝经期子宫小肌瘤的临床效果。方法:选取嘉兴市妇幼保健院2018年1月至2019年3月收治的围绝经期子宫小肌瘤患者104例为研究对象，采用随机数字表法分为对照组52例、观察组52例。对照组采用常规剂量米非司酮（25 mg/d）治疗，观察组采用低剂量米非司酮（12.5 mg/d）治疗，两组疗程均为3个月，观察两组临床疗效及安全性。结果:观察组总有效率为94.23%（49/52），高于对照组的76.92%（40/52），不良反应发生率为3.85%（2/52），低于对照组的21.15%（11/52），两组差异均有统计学意义（χn 2=6.310、7.120，均n P0.05）；治疗后，观察组VEGF、TNF-α、IGF-1分别为（150.12±18.54）ng/L、（22.88±6.24）ng/L、（78.48±10.15）ng/L，对照组分别为（184.72±27.36）ng/L、（29.16±7.32）ng/L、（92.35±12.54）ng/L，两组差异均有统计学意义（n t=7.549、4.708、6.200，均n P<0.05）。两组生活质量评分差异均有统计学意义（n t=15.756、18.663、19.027、15.191、36.367，均n P<0.05）。n 结论:低剂量米非司酮治疗围绝经期子宫小肌瘤临床效果优于常规剂量，安全性高。“,”Objective:To investigate the clinical effect of low-dose mifepristone on uterine fibroids in perimenopausal women.Methods:A total of 104 perimenopausal patients with uterine fibroids who received treatment in Jiaxing Maternity and Child Health Care Hospital from January 2018 to March 2019 were included in this study. They were randomly assigned to undergo treatment with either conventional-dose mifepristone (25 mg/d, control group, n n = 52) or low-dose mifepristone (12.5 mg/d, observation group, n n = 52) for 3 months. Clinical efficacy and drug safety were compared between the observation and control groups.n Results:Total effective rate in the observation group was significantly higher than that in the control group [94.23% (49/52) n vs. 76.92% (40/52), χn 2 = 6.310, n P < 0.05]. The incidence of adverse reactions in the observation group was significantly lower than that in the control group [3.85% (2/52) n vs. 21.15% (11/52), χn 2 = 7.120, n P 0.05). After treatment, serum levels of vascular endothelial growth factor, tumor necrosis factor-alpha and insulin-like growth factor-1 were (150.12 ± 18.54) ng/L, (22.88 ± 6.24) ng/L, (78.48 ± 10.15) ng/L respectively in the observation group, and they were (184.72 ± 27.36) ng/L, (29.16 ± 7.32) ng/L and (92.35 ± 12.54) ng/L respectively in the control group. There were significant differences in these serum indicators between the observation and control groups ( n t = 7.549, 4.708, 6.200, all n P < 0.05). Significant differences in the scores of quality of life were observed between the two groups ( n t = 15.756, 18.663, 19.027, 15.191, 36.367, all n P < 0.05).n Conclusion:Low-dose mifepristone in the treatment of uterine fibroids in perimenopausal women exhibits better clinical efficacy with higher safety than conventional-dose mifepristone.